Article
Oncology
Alexander Heinzel, Daniela Dedic, Norbert Galldiks, Philipp Lohmann, Gabriele Stoffels, Christian P. Filss, Martin Kocher, Filippo Migliorini, Kim N. H. Dillen, Stefanie Geisler, Carina Stegmayr, Antje Willuweit, Michael Sabel, Marion Rapp, Michael J. Eble, Marc Piroth, Hans Clusmann, Daniel Delev, Elena K. Bauer, Garry Ceccon, Veronika Dunkl, Jurij Rosen, Caroline Tscherpel, Jan-Michael Werner, Maximilian I. Ruge, Roland Goldbrunner, Jurgen Hampl, Carolin Weiss Lucas, Ulrich Herrlinger, Gabriele D. Maurer, Joachim P. Steinbach, Joerg Mauler, Wieland A. Worthoff, Bernd N. Neumaier, Christoph Lerche, Gereon R. Fink, Nadim Jon Shah, Felix M. Mottaghy, Karl-Josef Langen
Summary: PET imaging using O-(2-[F-18]fluoroethyl)-L-tyrosine (FET) as a tracer has become essential for diagnosing brain tumors, with increasing demand seen for differentiating tumor progress and treatment-related changes. Referring physicians rate FET PET highly for diagnosing recurrent gliomas and brain metastases.
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Seo Young Kang, Yunejeong Jang, Min-Sun Cho, Soo Jeong Park, Byung Seok Moon, Hye Ok Kim, Hai-Jeon Yoon, Bom Sahn Kim
Summary: A 49-year-old man presented with sudden right-sided weakness and seizure. Imaging studies revealed a cystic mass in the left parietal lobe with features more consistent with a brain abscess than a tumor.
CLINICAL NUCLEAR MEDICINE
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Norbert Galldiks, Philipp Lohmann, Gereon R. Fink, Karl-Josef Langen
Summary: For decades, amino acid PET tracers have been used to optimize diagnostics in brain tumor patients, with clinical indications including differentiation of neoplasm from nonneoplastic etiologies, delineation of tumor extent for further diagnostic and treatment planning, differentiation of treatment-related changes, and assessment of response to anticancer therapy. This article focuses on the diagnostic value of amino acid PET for patients with glioblastoma or metastatic brain cancer.
JOURNAL OF NUCLEAR MEDICINE
(2023)
Article
Oncology
Hamza Chegraoui, Cathy Philippe, Volodia Dangouloff-Ros, Antoine Grigis, Raphael Calmon, Nathalie Boddaert, Frederique Frouin, Jacques Grill, Vincent Frouin
Summary: Deep learning segmentation models can be split into object detection and segmentation steps, allowing trained networks on common lesions to be applied to rare ones without extra fine-tuning. This strategy enables robust segmentation inference even in unseen rare tumor regions.
Article
Radiology, Nuclear Medicine & Medical Imaging
Zhicong Li, Lena Kaiser, Adrien Holzgreve, Viktoria C. Ruf, Bogdana Suchorska, Vera Wenter, Stefanie Quach, Jochen Herms, Peter Bartenstein, Joerg-Christian Tonn, Marcus Unterrainer, Nathalie L. Albert
Summary: The study aimed to evaluate radiomic features extracted from dynamic [F-18]FET PET images for predicting TERTp-mutation status in patients with IDH-wildtype high-grade glioma, with the time-to-peak model showing the highest predictability.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Olivia Kertels, Juergen Krauss, Camelia Maria Monoranu, Samuel Samnick, Alexander Dierks, Malte Kircher, Milena I. Mihovilovic, Mirko Pham, Andreas K. Buck, Matthias Eyrich, Paul-Gerhardt Schlegel, Michael C. Fruehwald, Brigitte Bison, Constantin Lapa
Summary: This retrospective study analyzed the diagnostic utility and impact on clinical management of [F-18]FET-PET in 21 pediatric and adolescent patients with CNS tumors. The results showed that [F-18]FET-PET had an impact on the treatment decisions of 14 patients, including avoidance of invasive surgery or biopsy, biopsy guidance, change of treatment, and confirmation of diagnosis.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Zhicong Li, Adrien Holzgreve, Lena M. Unterrainer, Viktoria C. Ruf, Stefanie Quach, Laura M. Bartos, Bogdana Suchorska, Maximilian Niyazi, Vera Wenter, Jochen Herms, Peter Bartenstein, Joerg-Christian Tonn, Marcus Unterrainer, Nathalie L. Albert, Lena Kaiser
Summary: This study built and evaluated a prediction model using clinical parameters and radiomic features extracted from [F-18]FET PET for survival stratification in patients with newly diagnosed IDH-wildtype glioblastoma. The model achieved high predictability of short-term survival and improved patient stratification beyond established prognostic markers.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Multidisciplinary Sciences
Maciej Harat, Jozefina Rakowska, Marek Harat, Tadeusz Szylberg, Jacek Furtak, Izabela Miechowicz, Bogdan Malkowski
Summary: By adding FET/PET imaging, the accuracy of defining malignant areas of contrast-enhancing gliomas can be improved. This is crucial for the management of adult-type diffuse gliomas.
NATURE COMMUNICATIONS
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Cornelia Brendle, Caroline Maier, Benjamin Bender, Jens Schittenhelm, Frank Paulsen, Mirjam Renovanz, Constantin Roder, Salvador Castaneda-Vega, Ghazaleh Tabatabai, Ulrike Ernemann, Christian la Fougere
Summary: Multiparametric PET/MRI with F-18-FET enables the simultaneous assessment of brain tumor characteristics, and has a significant impact on diagnosis and clinical management. It can accurately identify malignancy and distinguish tumor progression from therapy-related imaging alterations, providing valuable information for treatment decisions.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Review
Oncology
Jules Tianyu Zhang-Yin, Antoine Girard, Marc Bertaux
Summary: This article provides a review of the current place and perspectives of positron emission tomography (PET) imaging in the diagnosis and follow-up of primary and secondary brain tumors. Different PET radiotracers are used to accurately depict brain tumors and provide unique metabolic and biologic information. PET imaging is increasingly used to supplement MRI in the clinical management of brain tumors. The main radiotracers implemented in clinical practice include [F-18]FDG, radiolabeled amino acids, and [Ga-68]Ga-DOTA-SSTR.
Review
Oncology
Adrien Holzgreve, Nathalie L. Albert, Norbert Galldiks, Bogdana Suchorska
Summary: The use of positron emission tomography (PET) imaging in neuro-oncological surgery is vital for interpretation of imaging findings, treatment interventions, and surgical planning in patients with glioma, brain metastases, and meningioma. Advances in PET technology, such as amino acid tracers and specific ligands, provide promising perspectives for non-invasive prediction of molecular tumor characteristics, response assessment, and differentiation between tumor progression and treatment-related changes. Further developments in neuro-oncological imaging are expected from new techniques like hybrid PET/MR scanners and artificial intelligence methods.
Article
Radiology, Nuclear Medicine & Medical Imaging
Eike Steidl, Karl-Josef Langen, Sarah Abu Hmeidan, Nenad Polomac, Christian P. Filss, Norbert Galldiks, Philipp Lohmann, Fee Keil, Katharina Filipski, Felix M. Mottaghy, Nadim Jon Shah, Joachim P. Steinbach, Elke Hattingen, Gabriele D. Maurer
Summary: The retrospective analysis evaluated the diagnostic value of consecutive PWI and [F-18]FET PET, showing that the combination of both methods can improve overall accuracy. Under specific conditions, PWI outperformed [F-18]FET PET for certain tumors. These results emphasize the importance of sequential use of PWI and [F-18]FET PET in clinical diagnosis.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Annaleis Tatkovic, Rhiannon McBean, Ebony Perkins, David Wong
Summary: In neuro-oncology imaging, a positive correlation was observed between the maximum standard uptake value (SUV) on F-18-FET PET and the World Health Organization (WHO) grade in glioma. Further studies are recommended to explore this relationship.
JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY
(2022)
Article
Oncology
Reda Stankunaite, Sally L. George, Lewis Gallagher, Sabri Jamal, Ridwan Shaikh, Lina Yuan, Debbie Hughes, Paula Z. Proszek, Paul Carter, Grzegorz Pietka, Timon Heide, Chela James, Haider Tari, Claire Lynn, Neha Jain, Laura Rey Portela, Tony Rogers, Sucheta J. Vaidya, Julia C. Chisholm, Fernando Carceller, Elwira Szychot, Henry Mandeville, Paola Angelini, Angela B. Jesudason, Michael Jackson, Lynley Marshall, Susanne A. Gatz, John Anderson, Andrea Sottoriva, Louis Chesler, Michael Hubank
Summary: This study developed a clinically relevant NGS capture panel and workflow for detecting low frequency genetic variants in cell-free DNA from children with solid tumors. The method showed high sensitivity, specificity, repeatability, and reproducibility. The potential for clinical application was demonstrated in childhood cancer patients, with a close correlation between cfDNA events and treatment response observed.
EUROPEAN JOURNAL OF CANCER
(2022)
Review
Oncology
Paolo Pedrazzoli, Giovanni Rosti, Eleonora Soresini, Silvia Ciani, Simona Secondino
Summary: Germ cell tumors (GCTs) are a solid tumor type curable in most patients, with specific biochemical markers such as HCG, AFP, and LDH used for diagnosis and monitoring. Recent studies are exploring the use of miRNAs as serum biomarkers. Serum tumor markers play a crucial role in the diagnosis, staging, prognosis, monitoring of response, and follow-up of GCTs.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Article
Oncology
Michael M. Wollring, Jan-Michael Werner, Elena K. Bauer, Caroline Tscherpel, Garry S. Ceccon, Philipp Lohmann, Gabriele Stoffels, Christoph Kabbasch, Roland Goldbrunner, Gereon R. Fink, Karl-Josef Langen, Norbert Galldiks
Summary: This study evaluated the use of FET PET and MRI for early response assessment in recurrent glioma patients treated with lomustine-based chemotherapy. The results suggest that FET PET provides complementary information to RANO criteria for response evaluation early after treatment initiation.
Review
Oncology
Michael M. Wollring, Jan-Michael Werner, Garry Ceccon, Philipp Lohmann, Christian P. Filss, Gereon R. Fink, Karl-Josef Langen, Norbert Galldiks
Summary: PET imaging using radiolabeled amino acids combined with MRI is a valuable diagnostic tool in managing brain tumor patients. This review provides an overview of PET studies in glioma patients with IDH mutation, which typically do not show contrast enhancement on MRI. The review focuses on the role of amino acid PET in differential diagnosis, treatment planning, and response assessment in patients with IDH-mutant gliomas.
JOURNAL OF NEURO-ONCOLOGY
(2023)
Article
Oncology
J. Weller, N. Schaefer, C. Schaub, T. Tzaridis, T. Zeyen, M. Schneider, A. L. Potthoff, F. A. Giordano, J. P. Steinbach, P. S. Zeiner, T. Kowalski, M. Sabel, P. Hau, D. Krex, O. Grauer, R. Goldbrunner, O. Schnell, G. Tabatabai, F. Ringel, F. Schmidt-Graf, S. Brehmer, J. C. Tonn, L. Bullinger, P. Vajkoczy, M. Glas, H. Vatter, U. Herrlinger, C. Seidel
Summary: In the CeTeG/NOA-09 randomized phase III trial, TMZ/CCNU combination therapy was found to be superior to TMZ in newly diagnosed MGMT methylated glioblastoma, with higher incidence of hematotoxicity. This study analyzed high-grade hematotoxicity and its prognostic relevance in the trial population.
JOURNAL OF NEURO-ONCOLOGY
(2023)
Article
Oncology
Cornelis M. de Mooij, Thiemo J. A. van Nijnatten, Briete Goorts, Loes F. S. Kooreman, Isabel W. M. Raymakers, Silke P. L. van Meijl, Maaike de Boer, Kristien B. M. I. Keymeulen, Joachim E. Wildberger, Felix M. Mottaghy, Marc B. I. Lobbes, Marjolein L. Smidt
Summary: This study investigated the feasibility of sequential hybrid [18F]FDG PET/MRI in predicting the treatment response in breast cancer patients undergoing neoadjuvant chemo(targeted) therapy. The qualitative or quantitative evaluation of PET/MRI after therapy was found to be unreliable in predicting the response of the primary tumor and axillary lymph nodes. However, combining the relative decrease in PET and MR imaging variables halfway through therapy improved the diagnostic accuracy, especially for predicting the response of axillary lymph nodes. These findings suggest that sequential hybrid [18F]FDG PET/MRI may have complementary value in the early prediction of treatment response in breast cancer.
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Isabelle Stetter, Jan-Michael Werner, Michael Schroeter, Claudia Baumann, Janina Neuneier, Marc Schlamann, Matthias Schmidt, Alexander Drzezga, Gereon R. Fink, Norbert Galldiks
Summary: Differentiating brain tumors from nonneoplastic lesions using conventional MRI may be challenging. Clinical symptoms often remain unspecific, and imaging findings from MRI may be inconclusive. PET with the radiolabeled somatostatin receptor ligand DOTATATE was performed, and it facilitated the diagnosis of a falcine meningioma consistent with its value for the differential diagnosis of meningioma.
CLINICAL NUCLEAR MEDICINE
(2023)
Article
Oncology
Alexander Heinzel, Felix M. Mottaghy, Christian Filss, Gabriele Stoffels, Philipp Lohmann, Michel Friedrich, Nadim J. Shah, Svenja Caspers, Carolin Weiss Lucas, Maximilian I. Ruge, Norbert Galldiks, Gereon R. Fink, Karl-Josef Langen, Martin Kocher
Summary: This study investigated the impact of tumor development and multimodality therapy on health-related quality of life (HRQoL) in glioma patients. The results showed that right hemisphere gliomas were associated with less favorable outcomes in most functional domains except communication ability. This relationship was mainly observed in T2/FLAIR lesions involving structural and functional networks in the right hemisphere.
JOURNAL OF NEURO-ONCOLOGY
(2023)
Letter
Oncology
Richard Drexler, Jennifer Goettsche, Thomas Sauvigny, Ulrich Schueller, Robin Khatri, Fabian Hausmann, Sonja Haenzelmann, Tobias B. Huber, Stefan Bonn, Dieter H. Heiland, Daniel Delev, Varun Venkataramani, Frank Winkler, Johannes Weller, Thomas Zeyen, Ulrich Herrlinger, Jens Gempt, Franz L. Ricklefs, Lasse Duehrsen
Letter
Oncology
Jan-Michael Werner, Michael M. Wollring, Caroline Tscherpel, Elena K. Rosen, Lisa Werr, Isabelle Stetter, Daniel Ruess, Maximilian Ruge, Anna Brunn, Abdulkader Al Shughri, Christoph Kabbasch, Gereon R. Fink, Karl-Josef Langen, Norbert Galldiks
Article
Multidisciplinary Sciences
Marco M. E. Vogel, Arthur Wagner, Jens Gempt, Harald Krenzlin, Thomas Zeyen, Richard Drexler, Martin Voss, Charlotte Nettekoven, Tammam Abboud, Dorothee Mielke, Veit Rohde, Marco Timmer, Roland Goldbrunner, Joachim P. Steinbach, Lasse Duehrsen, Manfred Westphal, Ulrich Herrlinger, Florian Ringel, Bernhard Meyer, Stephanie E. Combs
Summary: This study evaluated the impact of COVID-19 on patients with high-grade glioma and provided treatment recommendations. The results showed that overall survival for high-grade glioma improved during the pandemic, and there were no significant differences in treatment patterns and time intervals. Therefore, it is recommended to continue treating high-grade glioma according to the latest guidelines and standards of care.
SCIENTIFIC REPORTS
(2023)
Article
Cell Biology
Amelie Heesch, Lars Ortmanns, Jochen Maurer, Elmar Stickeler, Sabri E. M. Sahnoun, Felix M. Mottaghy, Agnieszka Morgenroth
Summary: Recent studies have shown that PSMA expression on TNBC cells and adjacent endothelial cells may serve as a new target for therapy. This study analyzed the expression of PSMA and its isoforms in TNBC cells, BCSCs, and tumor-associated endothelial cells. The results demonstrated that PSMA was highly expressed in TNBC cell lines and its isoforms were predominantly found in BCSCs. In addition, tumor-conditioned media had a significant pro-angiogenic effect and all TNBC cell lines induced PSMA expression in HUVEC. These findings suggest the potential of PSMA-targeted therapy in TNBC.
Article
Oncology
Maximilian Niyazi, Nicolaus Andratschke, Martin Bendszus, Anthony J. Chalmers, Sara C. Erridge, Norbert Galldiks, Frank J. Lagerwaard, Pierina Navarria, Per Munck af Rosenschoeld, Umberto Ricardi, Martin J. van den Bent, Michael Weller, Claus Belka, Giuseppe Minniti
Summary: This guideline aims to update the existing European consensus on delineation of the clinical target volume (CTV) in adult glioblastoma patients. It discusses key issues including pre-treatment steps, target delineation, and technical aspects of treatment. Based on the EORTC recommendation, a single CTV definition using post-operative contrast-enhanced T1 abnormalities is recommended, without the need to cone down. The PTV margin should be based on individual mask system and IGRT procedures, usually no greater than 3 mm.
RADIOTHERAPY AND ONCOLOGY
(2023)
Review
Oncology
Karl-Josef Langen, Norbert Galldiks, Joerg Mauler, Martin Kocher, Christian Peter Filss, Gabriele Stoffels, Claudia Regio Brambilla, Carina Stegmayr, Antje Willuweit, Wieland Alexander Worthoff, Nadim Jon Shah, Christoph Lerche, Felix Manuel Mottaghy, Philipp Lohmann
Summary: Advanced MRI methods and PET using radiolabelled amino acids provide valuable additional information for brain tumour diagnostics. While the hybrid PET/MRI has allowed for the convergence of these methods, simultaneous imaging has limited relevance in clinical neuro-oncology. A multimodal approach that combines PET and MRI shows promising improvement in the diagnosis of cerebral gliomas.
Article
Oncology
Julian P. Layer, Katharina Layer, Gustavo R. Sarria, Fred Roehner, Cas S. Dejonckheere, Lea L. Friker, Thomas Zeyen, David Koch, Davide Scafa, Christina Leitzen, Muemtaz Koeksal, Frederic Carsten Schmeel, Niklas Schaefer, Jennifer Landsberg, Michael Hoelzel, Ulrich Herrlinger, Matthias Schneider, Frank A. Giordano, Leonard Christopher Schmeel
Summary: This study evaluates the safety and outcome profile of five-fraction stereotactic radiotherapy (FSRT) for brain metastases (BM). It shows that FSRT is a feasible and efficient approach for both adjuvant and definitive treatment, with acceptable local control rates and comparable radiation necrosis rates.
